| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2011 | WO2011114271A1 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| 09/22/2011 | WO2011114249A1 A natural substance based antioxidant and chemoprotective agent and its method of production |
| 09/22/2011 | WO2011114246A1 Process for the preparation of malic acid salt of sunitinib |
| 09/22/2011 | WO2011114220A1 Neuro-protective effects of adelostemma gracillimum and its isolated compounds |
| 09/22/2011 | WO2011114184A1 Amides of heterocyclic compounds as trpa1 inhibitors |
| 09/22/2011 | WO2011114160A1 Anagrelide derivatives (imidazo [2, 1-b] quinazolin - 2 - ones ) as pde iii inhibitors useful as antithrombotic agents |
| 09/22/2011 | WO2011114148A1 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| 09/22/2011 | WO2011114137A1 Toluidine blue derivatives as photosensitising compounds |
| 09/22/2011 | WO2011114109A1 Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3 -methyl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide |
| 09/22/2011 | WO2011114103A1 Pyrimidinones for use as medicaments |
| 09/22/2011 | WO2011113988A1 New derivatives of propargylamine having neuroprotective capacity for the treatment of alzheimer's and parkinson's diseases |
| 09/22/2011 | WO2011113981A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 09/22/2011 | WO2011113965A1 Pharmaceutical composition in solid form containing isoflavones, a calcium salt and vitamin d3 |
| 09/22/2011 | WO2011113947A1 Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| 09/22/2011 | WO2011113904A1 Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| 09/22/2011 | WO2011113895A2 Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase iv (dp iv) |
| 09/22/2011 | WO2011113894A1 Pyridine and pyrazine derivative for the treatment of cf |
| 09/22/2011 | WO2011113892A2 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 09/22/2011 | WO2011113889A1 Modified u7 snrnas for treatment of neuromuscular diseases |
| 09/22/2011 | WO2011113862A1 Imidazopyrazines |
| 09/22/2011 | WO2011113855A2 Pharmaceutical composition for treatment of increased intraocular pressure |
| 09/22/2011 | WO2011113826A1 Novel topical corticosteroid formulation |
| 09/22/2011 | WO2011113802A2 Imidazopyridine compounds, compositions and methods of use |
| 09/22/2011 | WO2011113608A1 Esterified polysaccharide osmotic agents |
| 09/22/2011 | WO2011113606A1 Anti-infective compounds |
| 09/22/2011 | WO2011113600A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/22/2011 | WO2011113586A1 Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto |
| 09/22/2011 | WO2011113578A1 New oxadiazole derivatives |
| 09/22/2011 | WO2011113512A1 Morpholinylquinazolines |
| 09/22/2011 | WO2011113507A2 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 09/22/2011 | WO2011113370A1 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising these compounds |
| 09/22/2011 | WO2011113368A1 Preparation method of fluoro-substituted deuterated diphenylurea |
| 09/22/2011 | WO2011113367A1 Method and process for preparation and production of deuterated ω-diphenylurea |
| 09/22/2011 | WO2011113366A1 Method for preparing deuterated diphenylurea |
| 09/22/2011 | WO2011113363A1 Agomelatine hydrobromide hydrate and preparation thereof |
| 09/22/2011 | WO2011113362A1 Agomelatine hydrochloride hydrate and preparation thereof |
| 09/22/2011 | WO2011113361A1 Ceftizoxime sodium crystalline hydrate, preparation methods and uses thereof |
| 09/22/2011 | WO2011113351A1 [(4-methyl-2-propyl-n-methoxy-substituted phenylalkyl-1h-benzimidazol-6-formamide)-1-yl]-methyl biphenyl compounds and their preparation methods |
| 09/22/2011 | WO2011113320A1 Pharmaceutical compositions comprising dronedarone |
| 09/22/2011 | WO2011113309A1 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| 09/22/2011 | WO2011113301A1 Self-emulsifying formulation of taxanes and preparation method thereof |
| 09/22/2011 | WO2011113300A1 Medicines for inhibiting toxicity or side effects caused by chemotherapeutic agents |
| 09/22/2011 | WO2011113293A1 Dihydropteridinone derivatives, preparation method and pharmaceutical use thereof |
| 09/22/2011 | WO2011113284A1 Shikonin naphthazarin derivatives, preparation method and antitumor use thereof |
| 09/22/2011 | WO2011113203A1 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 09/22/2011 | WO2011113175A1 Cytarabine prodrug derivatives and use for resisting cancer or tumor thereof |
| 09/22/2011 | WO2011113174A1 Cytarabine derivatives and uses for anticancer and antitumor thereof |
| 09/22/2011 | WO2011113173A1 Cytarabine prodrug derivatives and use for resisting cancer or tumor thereof |
| 09/22/2011 | WO2011113128A1 Fish- and plant-oil-based preparations used as a nutritional supplement |
| 09/22/2011 | WO2011113118A1 Drug tolerance/persistence of fungal biofilms |
| 09/22/2011 | WO2011100502A8 7-aminofuropyridine derivatives |
| 09/22/2011 | WO2011094731A3 Methods for diagnosis and treatment of non-insulin dependent diabetes mellitus |
| 09/22/2011 | WO2011092720A3 Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts and process for their preparation |
| 09/22/2011 | WO2011088806A3 A method of industrial production of an amorphous form of atorvastatin with a high specific surface area and its use in a dosage form |
| 09/22/2011 | WO2011086575A3 A pharmaceutical composition for treatment respiratory tract infections |
| 09/22/2011 | WO2011084086A3 Hydrated pyrido(4,3-b)indole-based pharmaceutical composition for treating neurodegenerative diseases, method for producing same and pharmaceutical agent based thereon |
| 09/22/2011 | WO2011080510A8 Tricyclic compounds for use as kinase inhibitors |
| 09/22/2011 | WO2011074931A3 Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome |
| 09/22/2011 | WO2011063178A3 Intravenous infusion of curcumin and a calcium channel blocker |
| 09/22/2011 | WO2011059969A3 Mammalian metabolites of steroids |
| 09/22/2011 | WO2011059776A3 Prophylaxis of skin cancer with retinamides |
| 09/22/2011 | WO2011056599A3 Caged ceramide-1-phosphate derivatives |
| 09/22/2011 | WO2011056545A3 Antimicrobial ionic liquids |
| 09/22/2011 | WO2011056477A3 Methods for treating inflammation and oxidative stress related diseases |
| 09/22/2011 | WO2011053792A3 Methods and compositions for sustained delivery of drugs |
| 09/22/2011 | WO2011053003A3 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer |
| 09/22/2011 | WO2011050206A3 Compositions and methods for the treatment of sinonasal disorders |
| 09/22/2011 | WO2011050178A3 Targeted prdm gene or protein modulation therapeutic agents |
| 09/22/2011 | WO2011049979A3 Injectable formulations for intra- articular or peri-articular administration |
| 09/22/2011 | WO2011049908A3 Bismacrokyclic compounds as hepatitis c virus inhibitors |
| 09/22/2011 | WO2011049348A3 Antiviral agents obtained from curcuma longa, having inhibitory activities against avian influenza, swine influenza, and novel influenza |
| 09/22/2011 | WO2011046596A3 Anti-cancer tamoxifen-melatonin hybrid ligand |
| 09/22/2011 | WO2011025982A3 Tetracycline compounds |
| 09/22/2011 | WO2011025683A8 Hiv integrase inhibitors |
| 09/22/2011 | WO2011018474A8 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
| 09/22/2011 | WO2011009899A3 Phenalenones as antitumoral agents |
| 09/22/2011 | WO2010151799A9 Compounds for modulating rna binding proteins and uses therefor |
| 09/22/2011 | WO2010146370A3 Sox11 activating agents and uses thereof |
| 09/22/2011 | WO2010121676A3 Use of glycyrrhetic acid and/or derivatives thereof for the production of cosmetic or dermatological preparations for the prophylaxis of damage to skin dna and/or for repairing previously incurred damaged to skin dna |
| 09/22/2011 | WO2010095042A8 Pyridocarbazole type compounds and applications thereof |
| 09/22/2011 | WO2010093706A8 Chemically programmed vaccination |
| 09/22/2011 | WO2010053471A8 Modulators of atp-binding cassette transporters |
| 09/22/2011 | WO2009111653A3 Antiviral therapeutic agents |
| 09/22/2011 | WO2009037111A3 Method for the production of 1,3-dioxolane-2-ones and carboxylic acid esters by means of transacylation in basic reaction conditions |
| 09/22/2011 | US20110231942 Tiki1 and tiki2, wnt inhibitors |
| 09/22/2011 | US20110230816 Gels for Transdermal Delivery |
| 09/22/2011 | US20110230662 Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging |
| 09/22/2011 | US20110230652 Use of lipid conjugates in the treatment of diseases |
| 09/22/2011 | US20110230566 Perfluorocarbon eye cream formulations |
| 09/22/2011 | US20110230564 Ant4 inhibitor compounds and methods of use thereof |
| 09/22/2011 | US20110230562 Melanins synthesized chemically or via enzyme catalysis |
| 09/22/2011 | US20110230561 Medical adhesive compositions |
| 09/22/2011 | US20110230560 Synergetic composition comprising flavouring substances and organic acids and use thereof |
| 09/22/2011 | US20110230559 Tranexamic Acid Formulations |
| 09/22/2011 | US20110230558 Use of cationic surfactants for the inactivation of toxins |
| 09/22/2011 | US20110230557 Polyunsaturated fatty acid and diol ester as an anti-acne agent |
| 09/22/2011 | US20110230556 Diglycidic Ether Derivative Therapeutics and Methods for Their Use |
| 09/22/2011 | US20110230555 Enzyme Inhibitors and the Use Thereof |
| 09/22/2011 | US20110230554 Method of Treating Viral Infections by Administration of Ethyl Mercury or Thiol Derivative Thereof |
| 09/22/2011 | US20110230553 Crystallized form of dronedarone base |